MarginsXMarginsX
Home › Markets › Health Care › NGNE

Neurogene Inc. Common Stock (NGNE)

NGNE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$23.30
-2.63% on the day
Market cap
$482.3M
Small cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$90.4M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1404644/000140464426000019/0001404644-26-000019-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNGNE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO year2014
SEC CIK0001404644

Financials · 2025

LineValue
Revenue$0
Net income-$90.4M
Operating income-$103.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$103.8M
Total assets$288.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
9.8 months
$78.9M cash at September 30, 2026
Share count, 1 year
+33.6%
2025-11-11 to 2026-11-05 · +781.1% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$1.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$78.9M cash; operating cash flow -$24.1M a quarter.Report 2026-09-30
Shares outstanding20,700,905 (2026-11-05); 15,489,800 a year earlier; 9,397,901 three years earlier. 3y figure adjusted for splits (1-for-4 overall).Cover page 2026-11-05
Reverse splits, 3 years1; latest 1-for-4 on 2023-12-19Source 2023-12-19
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-07-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Morristown, New Jersey, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$29.0M-$29.1M$78.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$34.5M-$23.8M$112.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$30.9M-$26.1M$124.2MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
$0-$24.7M-$17.4M$103.8MNo debt tags$010-K 2026-03-24
Q3 2025
2025-09-30
$0-$21.0M-$19.5M$71.0MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
$0-$22.0M-$19.5M$58.8MNo debt tagsNeeds four quarters10-Q 2025-08-11
Q1 2025
2025-03-31
Not filed-$22.6M-$20.8M$70.8MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
$0-$19.5M-$17.5M$136.6MNo debt tags$925K10-K 2026-03-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-5.5%
1 month+11.0%
3 months-32.8%
Year to date+16.2%
1 year-9.7%
From 52-week high-44.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
MNPRMonopar Therapeutics Inc.$71.97-0.04%$487.7M
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M
OCSOculis Holding AG$7.63-0.13%$469.9M
LYELLyell Immunopharma Inc.$14.65+2.45%$469.0M
KMDAKamada Ltd.$8.11+0.25%$468.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier